Research & Development
Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III
Do you recall what President Trump tweeted right after Merck's Kenneth Frazier resigned from his American Manufacturing Council?
Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug
Susan G. Komen and the Breast Cancer Research Foundation are focusing on raising awareness and research money for the deadliest forms of the disease.
AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials
This is likely due, in part, to the increasingly complex nature of new specialty drugs.
The drugmaker's video asks people in New York and San Francisco about their ideas for great inventions.
These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs
In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena
Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year
Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal
The merger of Quintiles and IMS Health closed in October.
The partnership allows Sermo to expand the reach of its research initiatives and Everyday Health to scale its targeted advertising on the social platform.
Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana
Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.
IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.
The scientific services company expands its portfolio to include expertise in oncology clinical studies.
The newly launched tools aim to reduce the time and costs of marketing new drugs by "debugging" the lab environment.
Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup
AstraZeneca and Sanofi to share compounds in rare agreement; FDA advisory committee votes against bladder cancer drug; Allergan may buyer in Pfizer deal
Executives at Eli Lilly, Merck and Biogen used the most recent earnings season to promote innovation and defend drug pricing.
The drugmaker, which recently drew scrutiny from lawmakers, is planning to change some of its most contentious business practices. Experts say Valeant also needs to educate lawmakers and the public about the value of its medicines.
Biogen to map ALS genes with Ice Bucket Challenge funds; Merck seeks first-line indication for Keytruda; lawmaker criticizes FDA approval of OxyContin for children